Enh3ance trial results indicate DTX301 reduces ammonia levels by 18% and supports dietary liberalization in patients with OTC deficiency.

Statistically significant improvements in primary endpoint of ammonia control compared with placebo at 36 weeks Clinically ...

Detailed price information for Usana Health Sciences Inc (USNA-N) from The Globe and Mail including charting and trades.

ECUR-506 is an investigational gene editing therapy that utilizes an adeno-associated virus to deliver a functional copy of the OTC gene. The Food and Drug Administration (FDA) has granted Fast Track ...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

PHILADELPHIA--(BUSINESS WIRE)--iECURE, a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver ...

- Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure) - ECUR-506 was generally well tolerated with no ...

PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with ...

PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver ...